Asif Suria

One Page Barron's Summary

Probably the following statement by the CEO Antonio Perez during the Kodak conference call when asked whether Kodak was on track for back to school <i>"I never said we’re going to be back to school. We’re still on track with our project. We are — I have no news really to report, and you know why I don’t want to report news until the closest possible time, the latest possible time. So but we keep investing in that business. We are accelerating things and I feel that we are in good shape, but there is nothing else to report."</i>

It is interesting to see the generic drug maker Teva (TEVA) back where it was a year ago. The run-up that started last year was in anticipation on looming patent expirations at big pharma companies like Pfizer (PFE) and Merck. I feel that the Zocor pricing move by Merck is likely to be negative for the generic drug companies like Teva, Ranbaxy, Mylan and Dr. Reddy's but would barely affect Pfizer. Pfizer raised its dividend about six months ago and I doubt they would do it again anytime soon.